WO2023138573A1 - 白细胞介素21及其受体复合物 - Google Patents

白细胞介素21及其受体复合物 Download PDF

Info

Publication number
WO2023138573A1
WO2023138573A1 PCT/CN2023/072595 CN2023072595W WO2023138573A1 WO 2023138573 A1 WO2023138573 A1 WO 2023138573A1 CN 2023072595 W CN2023072595 W CN 2023072595W WO 2023138573 A1 WO2023138573 A1 WO 2023138573A1
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
seq
amino acid
complex
amino acids
Prior art date
Application number
PCT/CN2023/072595
Other languages
English (en)
French (fr)
Inventor
张喆
耿梦圆
芦迪
霍永庭
Original Assignee
广东菲鹏制药股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 广东菲鹏制药股份有限公司 filed Critical 广东菲鹏制药股份有限公司
Publication of WO2023138573A1 publication Critical patent/WO2023138573A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to the technical field of biomedicine, in particular to a disulfide-bond modified polypeptide complex comprising interleukin 21 and its receptor, and its use as a therapeutic agent, especially as a therapeutic agent for diseases such as cancer.
  • Cytokines play an important role in human immune regulation, and also participate in the immune regulation of tumors, which are closely related to the occurrence and development of tumors.
  • cytokines can directly act on immune effector cells in the tumor microenvironment to enhance the tumor suppressive effect.
  • many cytokines have been proven to have significant anti-tumor activity, and several cytokines have been approved by the FDA for marketing.
  • Interleukin 21 (IL-21), discovered in 2000, is a member of the Small four ⁇ -helix bundle family of cytokines and is mainly secreted by CD4+ T cells and NKT cells. It is an effective anti-tumor immune stimulator mediated by T cells and natural killer cells.
  • IL-21 contains approximately 162 amino acids (aa), forming a 14 kDa four-helix bundle.
  • IL-21 binds to the IL-21 receptor (IL-21R), which is a heterodimeric complex IL-21 receptor chain (IL-21R ⁇ or CD360) consisting of a common ⁇ chain (CD132 or ⁇ c) and a specific ⁇ chain.
  • IL-21R ⁇ is a transmembrane glycoprotein of 75kDa with 6 tyrosine residues in the cytoplasm, which is critical for IL-21 signal transduction.
  • the present invention aims to solve the problems of poor in vivo and in vitro stability, short half-life, poor product uniformity, or complex preparation process of IL-21 and IL-21R ⁇ in the construction of various types of fusion proteins to a certain extent.
  • the present invention relates to a polypeptide complex of IL-21 and IL-21R ⁇ , which is composed of a first polypeptide and a second polypeptide; wherein, the first polypeptide is a human IL-21 polypeptide or a functional fragment thereof; the second polypeptide is a human IL-21R ⁇ polypeptide or a functional fragment thereof; the first polypeptide or the second polypeptide has one or more amino groups
  • the acid site is mutated into Cys, which forms a disulfide bond with the Cys mutated into the corresponding amino acid site of the second polypeptide or the first polypeptide.
  • the amino acid Cys mutation site occurs at S4, S5, R10, I13, R14, Q17, I71, R81 or K82 on the IL-21 polypeptide or its functional fragment, and/or the amino acid Cys mutation site occurs at Y36, E38, A71, D72, S92, or A127 on the IL-21R ⁇ polypeptide or its functional fragment.
  • the amino acid site mutation of the polypeptide complex of IL-21 and IL-21R ⁇ is selected from one or more of the following mutation combinations: 1) the first polypeptide-R81C and the second polypeptide-E38C; 2) the first polypeptide-Q17C and the second polypeptide-A71C; 3) the first polypeptide-R14C and the second polypeptide-D72C; 4) the first polypeptide-S5C and the second polypeptide-S92C; 5) the first polypeptide-S4C and 6) the first polypeptide-R10C and the second polypeptide-D72C; 7) the first polypeptide-I13C and the second polypeptide-D72C; 8) the first polypeptide-I71C and the second polypeptide-A127C; and/or 9) the first polypeptide-K82C and the second polypeptide-Y36C.
  • the amino acid sequence of the first polypeptide in the polypeptide complex of IL-21 and IL-21R ⁇ is selected from amino acids 140-352 of SEQ ID NO: 2, amino acids 140-352 of SEQ ID NO: 4, amino acids 140-352 of SEQ ID NO: 6, amino acids 140-352 of SEQ ID NO: 8, NO: amino acid 140-352 of 10, amino acid 140-352 of SEQ ID NO: 12, amino acid 140-352 of SEQ ID NO: 14, amino acid 140-352 of SEQ ID NO: 16, or amino acid 140-352 of SEQ ID NO: 18.
  • the amino acid sequence of the second polypeptide in the polypeptide complex of IL-21 and IL-21R ⁇ is selected from amino acids 129-266 of SEQ ID NO: 1, amino acids 129-266 of SEQ ID NO: 3, amino acids 129-266 of SEQ ID NO: 5, amino acids 129-266 of SEQ ID NO: 7, NO: the 129th-266th amino acid of 15, or the 129th-266th amino acid of SEQ ID NO: 17.
  • the first polypeptide and/or the second polypeptide of the above-mentioned polypeptide complex of IL-21 and IL-21R ⁇ is covalently linked to the Fc fragment.
  • the present invention also relates to a vector comprising a nucleic acid as described above.
  • the invention also relates to host cells containing a nucleic acid as described above or a vector as described above.
  • the present invention also relates to a method for preparing the aforementioned IL-21 and IL-21R ⁇ polypeptide complex, comprising: 1) transforming a host cell with the above-mentioned vector; 2) cultivating the transformed host cell; 3) collecting the IL-21 and IL-21R ⁇ polypeptide complex expressed in the host cell.
  • the present invention also relates to a pharmaceutical composition, which comprises the above-mentioned IL-21 and IL-21R ⁇ polypeptide complex, the above-mentioned nucleic acid, the above-mentioned carrier, or the above-mentioned host cell and a pharmaceutically acceptable carrier, excipient, or stabilizer.
  • the present invention also relates to the application of the above-mentioned IL-21 and IL-21R ⁇ polypeptide complex in the preparation of medicines for treating diseases.
  • the present invention also relates to a method for treating or preventing a disease, said method comprising: administering to a patient The aforementioned IL-21 and IL-21R ⁇ polypeptide complex or the aforementioned pharmaceutical composition.
  • the aforementioned diseases may be infectious diseases, cancer, blood diseases and autoimmune diseases.
  • the above-mentioned cancers are preferably melanoma, colorectal cancer, skin cancer, lymphoma, renal cell carcinoma, solid tumor, liver cancer, lung cancer, gastric cancer, breast cancer;
  • the above-mentioned infectious diseases are preferably smallpox virus infection, HIV infection, bacterial infection, fungal infection, HBV infection;
  • the above-mentioned blood diseases are preferably anemia, acute myeloid leukemia, myelodysplastic syndrome, T-cell large granular lymphocytic leukemia; , gastritis, mucositis.
  • the above-mentioned IL-21 and IL-21R ⁇ polypeptide complex or pharmaceutical composition can be used alone or in combination with other drugs.
  • the above-mentioned other drugs are small molecule inhibitors or antibody drugs.
  • Figure 1 is a schematic diagram of the three-dimensional structure of IL-21/IL-21R ⁇ complex interaction
  • Figure 2 is a schematic diagram of the structure of an exemplary IL-21/IL-21R ⁇ complex fusion protein
  • Figure 3 is a schematic structural diagram of an exemplary IL-21/IL-21R ⁇ complex fusion protein in a specific application scenario
  • Figure 4 is the result of gel electrophoresis detection of IL-21/IL-21R ⁇ complex fusion protein modified by disulfide bond
  • Figure 5 shows the detection results of the binding ability (@TIGIT) of the fusion protein modified by disulfide bond and unmodified IL-21/IL-21R ⁇ complex to the targeting region.
  • Figure 6 shows the detection results of the binding ability (@PD-L1) of the fusion protein modified by the disulfide bond to reach the IL-21/IL-21R ⁇ complex.
  • Figure 7 shows the blocking detection results of the fusion protein paired with the target region (@TIGIT) modified by the disulfide bond and the unmodified IL-21/IL-21R ⁇ complex fusion protein.
  • amino acid refers to the twenty common naturally occurring amino acids.
  • Naturally occurring amino acids include alanine (Ala; A), arginine (Arg; R), asparagine (Asn; N), aspartic acid (Asp; D), cysteine (Cys; C); glutamic acid (Glu; E), glutamine (Gln; Q), glycine (Gly; G); histidine (His; H), isoleucine (Ile; I), leucine amino acid (Leu; L), lysine (Lys; K), methionine (Met; M), phenylalanine (Phe; F), proline (Pro; P), serine (Ser; S), threonine (Thr; T), tryptophan (Trp; W), tyrosine (Tyr; Y) and valine (Val; V).
  • Naturally occurring amino acids include alanine (Ala; A), arginine (Arg; R), asparagine (Asn;
  • polypeptide complex in the present invention refers to a protein formed by combining two different monomeric polypeptides.
  • the "fusion protein” in the present invention refers to the protein product obtained by gene recombination expressed under the control of the same regulatory sequence by linking the coding regions of two or more genes by gene recombination methods, chemical methods or other appropriate methods.
  • the first polypeptide is a monomeric protein obtained by fusion or non-fusion expression of IL-21 or a variant thereof and a biologically active polypeptide (such as an Fc fragment);
  • the second polypeptide is a monomeric protein obtained by fusion or non-fusion expression of IL-21R ⁇ or a variant thereof and a biologically active polypeptide (such as an Fc fragment).
  • the coding regions of two or more genes may be fused at one or several positions by a sequence encoding a peptide linker.
  • Peptide linkers can also be used to construct fusion proteins of the invention.
  • the "linker” of the present invention is used in the present invention to link IL-21 or IL-21R ⁇ and Fc variants to ensure correct folding and stability of the protein.
  • the "connecting peptide” of the present invention is preferably (GGGGS)nS, wherein n can be 0, 1, 2, 3, 4, 5 or more, preferably n is 2-4.
  • the "IL-21 or functional fragment" in the present invention can be IL-21 (interleukin 21) or its mutants of any species, such as human IL-21 or non-human mammal IL-21 or non-mammal IL-21.
  • exemplary non-human mammals such as pigs, rabbits, monkeys, orangutans, mice, etc., non-mammals such as chickens, etc.
  • it is human IL-21 or a functional fragment thereof.
  • the amino acid sequence of the mature molecule of human wild-type interleukin 21 is shown in SEQ ID NO: 9.
  • the numbering of all amino acid sites of IL-21 of the present invention is based on SEQ ID NO: 9, and the sequence numbering is from N-terminal to C-terminal.
  • the "IL-21 functional fragment" in the present invention refers to a mutant that has an impact on the biological function of IL-21 or changes in other properties through one or more amino acid substitutions, additions or deletion mutations.
  • amino acid changes can increase or decrease the interaction ability between IL-21 and its receptor; or such amino acid changes can increase or decrease the biological activity of IL-21, such as its ability to stimulate immune cell proliferation;
  • the "IL-21R ⁇ or its functional fragments" in the present invention can be IL-21R ⁇ or its mutants of any species, such as human IL-21R ⁇ or non-human mammal IL-21R ⁇ or non-mammal IL-21R ⁇ .
  • exemplary non-human mammals such as pigs, rabbits, monkeys, orangutans, mice, etc., non-mammals such as chickens, etc.
  • It is preferably human IL-21R ⁇ , more preferably human IL-21R ⁇ extracellular region, referred to as IL-21R ⁇ (SEQ ID NO: 11).
  • the numbering of all amino acid positions of IL-21R ⁇ in the present invention is based on SEQ ID NO: 11, and is numbered sequentially from N-terminus to C-terminus.
  • the "IL-21R ⁇ functional fragment” in the present invention refers to a molecule with human interleukin-21 receptor ⁇ activity obtained through one or more amino acid substitutions, insertions or deletion mutations.
  • the "Fc fragment” in the present invention refers to the constant region of the human immunoglobulin chain, especially the carboxy-terminal or a part of the constant region of the heavy chain of the immunoglobulin, which has no antigen binding activity and is the site where antibody molecules interact with effector molecules and cells.
  • an immunoglobulin Fc region may comprise two or more domains of heavy chains CH1, CH2, CH3, CH4 in combination with an immunoglobulin hinge region.
  • immunoglobulins can be divided into different classes, and there are mainly 5 classes of immunoglobulins: IgA, IgD, IgE, IgG and IgM. Some of these can be further divided into subclasses (isotypes), such as IgG-1, IgG-2, IgG-3, IgG-4; IgA-1 and IgA-2 and different genotypes.
  • the "Fc fragment” of the present invention preferably includes at least one immunoglobulin hinge region, and CH2 and CH3 regions of IgG. More preferably, it includes a CH2 domain of IgG1, a CH3 domain and an immunoglobulin hinge region, and the initial amino acid position of the hinge region can be changed.
  • the amino acid sequence of Fc in the present invention is shown in SEQ ID NO:13.
  • the "pharmaceutical composition” of the present invention means a mixture containing one or more compounds described herein or their physiologically/pharmaceutically acceptable salts or prodrugs and other chemical components, as well as other components such as physiologically/pharmaceutically acceptable carriers and excipients.
  • the purpose of the pharmaceutical composition is to promote the administration to the organism, facilitate the absorption of the active ingredient and thus exert biological activity.
  • the step of transforming host cells with recombinant DNA described in the present invention can be carried out by conventional techniques well known to those skilled in the art.
  • the obtained transformants can be cultured by conventional methods, and express the polypeptide encoded by the gene of the present invention.
  • the medium used during the culture can be selected from various conventional mediums according to the host cells used.
  • the host cells are cultured under conditions suitable for the growth of the host cells.
  • the crystal complex structure of IL-21 and IL-21R ⁇ (PDB ID: 3TGX, Figure 1) was chosen as the initial structure.
  • the contact interface residues located between IL-21 and IL-21R ⁇ were calculated from the structure, and the contact interface residues in the IL-21 and IL-21R ⁇ complex are shown in Table 1 below.
  • the IL-21 and IL-21R ⁇ complex provided by the present invention is composed of a first polypeptide and a second polypeptide; wherein, the first polypeptide is a human IL-21 polypeptide or a functional fragment thereof; the second polypeptide is a human IL-21R ⁇ polypeptide or a functional fragment thereof; the first polypeptide or the second polypeptide has one or more amino acid sites mutated to Cys, which pair with the corresponding second polypeptide or the Cys mutated at the amino acid site of the first polypeptide to form a disulfide bond.
  • the present invention constructs a stable protein complex with obvious anti-tumor activity and extended half-life in vivo by genetic engineering method, and the complex molecule contains Fc fusion protein molecules of IL-21 or its derivatives and IL-21R ⁇ or its derivatives.
  • amino acid sequence of the mature molecule of human wild-type interleukin 21 is shown in SEQ ID NO: 9, and all amino acid positions of IL-21 of the present invention are based on the amino terminal sequence of SEQ ID NO: 9.
  • IL-21R ⁇ The extracellular region of human IL-21R ⁇ , referred to as IL-21R ⁇ , has an amino acid sequence as shown in SEQ ID NO:11. All amino acid positions of IL-21R ⁇ in the present invention are based on the amino terminal sequence of SEQ ID NO: 11.
  • an exemplary usage scenario of an IL-21/IL-21R ⁇ complex is selected: the heavy chain variable region (VH) targeting the antigen is connected to IL-21R ⁇ through a Linker, and then connected to the N-terminal of the Fc of the antibody through a Hinge (its amino acid sequence is shown in SEQ ID NO: 21); the light chain variable region (VL) targeting the same antigen is connected to IL-21 through a Linker (its amino acid sequence is shown in SEQ ID NO: 24) to prepare a targeting IL -21/IL-21R ⁇ fusion protein.
  • the amino acid sequences of the heavy chains and light chains of exemplary complexes 1-9 are shown in Table 3 below, wherein the mutated Cys is underlined and bolded.
  • the amino acid sequence of Fc in this embodiment is shown in SEQ ID NO:13.
  • the above-mentioned fusion protein can be applied to molecules targeting the same antigen or target, such as the structure in Figure 3B or Figure 3C (the scfv targets the same antigen or target), and can also be used to target two or more antigens or target molecules, such as Figure 3A or Figure 3C (the scfv targets different antigens or targets).
  • the application scenarios of the fusion protein are not limited to the above examples.
  • Exemplary selection of an IL-21/IL-21R ⁇ complex usage scenario take Figure 3A as an example to prepare a fusion protein, one side is an antibody targeting TIGIT, and the other side is an antibody targeting PD-L1, and the amino acid sequences of the heavy chain and light chain of the antibody targeting PD-L1 are shown in SEQ ID NO: 19 and SEQ ID NO: 20, respectively.
  • the plasmid containing the target gene is introduced into the host cell Expi293 after forming a cationic complex with the transfection reagent PEI. Transcription and translation to obtain the target protein.
  • Expi293 cells were cultured at 37°C, 8% carbon dioxide, and 130rpm, and the cells were counted before transfection.
  • the 2E6 cells were inoculated into 1L shake flasks, and the culture system was about 300mL.
  • the transient cell expression solution was centrifuged at 9000rpm/20min, the supernatant was collected, and then sterilized and filtered through a 0.22 ⁇ m filter membrane.
  • Purification using ProA affinity chromatography the process is as follows: use AKTA york150 chromatography equipment, equilibrate the chromatography column (such as MabSelectSuRe LX, GE) with at least 5CV equilibration buffer (10mM PBS), load the sample to the chromatography column, so that the target protein is adsorbed on the chromatography column while other impurities are separated through penetration.
  • equilibration buffer 10mM PBS
  • the binding activity of the double antibody molecule (TIGIT end) to CHO-TIGIT cells was detected by FCM assay.
  • the binding activity of the double antibody molecule (PD-L1 end) to CHO-PD-L1 cells was detected by FCM assay.
  • the binding activity of the double antibody molecule (TIGIT end) blocking ligand to CHO-TIGIT cells was detected by FCM assay.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

一种包含白细胞介素21及其受体的二硫键改造多肽复合物。IL-21和IL-21Rα之间具有一个形成于IL-21的第一突变残基和IL-21Rα的第二突变残基之间的非天然的链间键，从而可以增强白细胞介素21及其受体复合物的稳定性。

Description

白细胞介素21及其受体复合物
优先权声明
本申请要求申请号为202210077607.4，申请日为2022年1月21日，发明名称为白细胞介素21及其受体复合物的中国发明专利申请的优先权，其全部内容通过引用并入本文中。
技术领域
本发明涉及生物医药技术领域，具体而言，涉及一种包含白细胞介素21及其受体的二硫键改造多肽复合物，以及其作为治疗剂特别是作为癌症等疾病治疗剂的用途。
背景技术
细胞因子在人体免疫调节中起重要作用，同时也参与肿瘤的免疫调控，与肿瘤的发生、发展密切相关。在免疫疗法中，细胞因子可直接作用于肿瘤微环境中的免疫效应细胞，增强肿瘤抑制效果。通过临床研究以及动物实验，许多细胞因子已被证明具有显著的抗肿瘤活性，已有多个细胞因子获得FDA批准上市。
白细胞介素21(IL-21)，于2000年被发现，属于四个小α螺旋束细胞因子家族(Small fourα-helix bundle family of cytokines)中的成员，主要由CD4+T细胞和NKT细胞分泌，它是一种有效的T细胞和自然杀伤细胞介导的抗肿瘤免疫刺激剂。
IL-21约含有162个氨基酸(aa)，形成一个14kDa的四螺旋束。IL-21与IL-21受体(IL-21R)结合，IL-21R是由普通γ链(CD132或γc)和特异性γ链组成的异二聚体复合物IL-21受体链(IL-21Rα或CD360)。IL-21Rα是一种跨膜糖蛋白75kDa，胞浆内6个酪氨酸残基，对IL-21信号传导至关重要。
近年来，IL-21及IL-21受体更多地用于构建融合蛋白，以改善其体内半衰期短，重复给药时剂量不好控制等问题，为了提高融合蛋白的稳定性，特提出本申请。
发明内容
本发明旨在一定程度上解决IL-21及IL-21Rα在构建各种类型的融合蛋白时存在的体内外稳定性差、半衰期短、产品均一性差、或制备工艺复杂的问题。
本发明涉及一种IL-21及IL-21Rα的多肽复合物，其由第一多肽和第二多肽组成；其中，第一多肽为人IL-21多肽或其功能性片段；第二多肽为人IL-21Rα多肽或其功能性片段；第一多肽或第二多肽上具有一个或多个氨基 酸位点突变成Cys，与对应的第二多肽或第一多肽氨基酸位点上突变成的Cys配对形成二硫键。
在本发明的一些具体实施方式中，上述的氨基酸Cys突变位点发生在IL-21多肽或其功能片段上的S4、S5、R10、I13、R14、Q17、I71、R81或K82上，和/或所述的氨基酸Cys突变位点发生在IL-21Rα多肽或其功能性片段上的Y36、E38、A71、D72、S92、或A127上。
在本发明的一些具体实施方式中，上述IL-21及IL-21Rα的多肽复合物的氨基酸位点突变选自以下突变组合中的一组或多组：1)第一多肽-R81C和第二多肽-E38C；2)第一多肽-Q17C和第二多肽-A71C；3)第一多肽-R14C和第二多肽-D72C；4)第一多肽-S5C和第二多肽-S92C；5)第一多肽-S4C和第二多肽-S92C；6)第一多肽-R10C和第二多肽-D72C；7)第一多肽-I13C和第二多肽-D72C；8)第一多肽-I71C和第二多肽-A127C；和/或9)第一多肽-K82C和第二多肽-Y36C。
在本发明的一些具体实施方式中，上述IL-21及IL-21Rα的多肽复合物中的第一多肽的氨基酸序列选自SEQ ID NO：2的第140位-352位氨基酸、SEQ ID NO：4的第140位-352位氨基酸、SEQ ID NO：6的第140位-352位氨基酸、SEQ ID NO：8的第140位-352位氨基酸、SEQ ID NO：10的第140位-352位氨基酸、SEQ ID NO：12的第140位-352位氨基酸、SEQ ID NO：14的第140位-352位氨基酸、SEQ ID NO：16的第140位-352位氨基酸、或SEQ ID NO：18的第140位-352位氨基酸。
在本发明的一些具体实施方式中，上述IL-21及IL-21Rα的多肽复合物中的第二多肽的氨基酸序列选自SEQ ID NO：1的第129位-266位氨基酸、SEQ ID NO：3的第129位-266位氨基酸、SEQ ID NO：5的第129位-266位氨基酸、SEQ ID NO：7的第129位-266位氨基酸、SEQ ID NO：15的第129位-266位氨基酸、或SEQ ID NO：17的第129位-266位氨基酸。
在本发明的一些具体实施方式中，上述IL-21及IL-21Rα的多肽复合物的第一多肽和/或第二多肽与Fc片段共价连接。
本发明还涉及含有如上所述的核酸的载体。
本发明还涉及含有如上所述的核酸或者如上所述的载体的宿主细胞。
本发明还涉及制备上述的IL-21及IL-21Rα多肽复合物的方法，包括：1)用如上所述的载体转化宿主细胞；2)培养所转化的宿主细胞；3)收集宿主细胞中表达的IL-21及IL-21Rα多肽复合物。
本发明还涉及药物组合物，其包含如上所述的IL-21及IL-21Rα多肽复合物、如上所述的的核酸、如上所述的载体、或如上所述的宿主细胞和药学上可接受的载体，赋形剂，或稳定剂。
本发明还涉及如上所述的IL-21及IL-21Rα多肽复合物在制备用于治疗疾病的药物中的应用。
本发明还涉及一种治疗或预防疾病的方法，所述方法包括：向患者施予 如前所述的IL-21及IL-21Rα多肽复合物或如前所述的药物组合物。
在本发明的一些具体实施方式中，上述的疾病可以为传染病、癌症、血液病和自身免疫性疾病。上述的癌症优选黑色素瘤、结直肠癌、皮肤癌、淋巴瘤、肾细胞癌、实体瘤、肝癌、肺癌、胃癌、乳腺癌；上述的传染病优选天花病毒感染、HIV感染、细菌感染、真菌感染、HBV感染；上述的血液病优选贫血、急性髓系白血病、骨髓增生异常综合征、T-细胞大颗粒淋巴细胞性白血病；上述的自身免疫性疾病优选多发性硬化症、银屑病、风湿性关节炎、炎性疾病、胃炎、黏膜炎。
在本发明的一些具体实施方式中，上述的IL-21及IL-21Rα多肽复合物或药物组合物可以单独使用，也可以与其它药物联合使用。上述其它药物为小分子抑制剂或抗体类药物。
附图说明
为了更清楚地说明本发明实施方式的技术方案，下面将对实施方式中所需要使用的附图作简单地介绍，应当理解，以下附图仅示出了本发明的某些实施方式，因此不应被看作是对范围的限定，对于本领域普通技术人员来讲，在不付出创造性劳动的前提下，还可以根据这些附图获得其他相关的附图。
图1为IL-21/IL-21Rα复合物相互作用立体结构示意图；
图2为示例性的IL-21/IL-21Rα复合物融合蛋白结构示意图；
图3为示例性的IL-21/IL-21Rα复合物融合蛋白具体应用场景结构示意图；
图4为经二硫键改造的IL-21/IL-21Rα复合物融合蛋白凝胶电泳检测结果；
图5为经二硫键改造的与未改造的IL-21/IL-21Rα复合物融合蛋白对靶向区结合力(@TIGIT)的检测结果。
图6为经二硫键改造的与未改造达到IL-21/IL-21Rα复合物融合蛋白对靶向区结合力(@PD-L1)的检测结果。
图7为经二硫键改造的与未改造的IL-21/IL-21Rα复合物融合蛋白对与靶向区结合力(@TIGIT)的阻断检测结果。
具体实施方式
为了更容易理解本发明，以下具体定义了某些技术和科学术语。除非在本文中另有明确定义，本文使用的所有其它技术和科学术语都具有本发明所属领域的普通技术人员通常理解的含义。
在本发明中，术语“氨基酸(amino acid)”是指二十个常见的天然存在的氨基酸。天然存在的氨基酸包括丙氨酸(Ala；A)、精氨酸(Arg；R)、天冬酰胺(Asn；N)、天冬氨酸(Asp；D)、半胱氨酸(Cys；C)；谷氨酸(Glu；E)、谷氨酰胺(Gln；Q)、甘氨酸(Gly；G)；组氨酸(His；H)、异亮氨酸(Ile；I)、亮 氨酸(Leu；L)、赖氨酸(Lys；K)、甲硫氨酸(Met；M)、苯丙氨酸(Phe；F)、脯氨酸(Pro；P)、丝胺酸(Ser；S)、苏氨酸(Thr；T)、色氨酸(Trp；W)、酪氨酸(Tyr；Y)和缬氨酸(Val；V)。
本发明所述的“多肽复合物”是指两个不同的单体多肽结合而成的蛋白。
本发明所述的“融合蛋白”是指，通过用基因重组方法、化学方法或其它适当方法将两个或多个基因的编码区连接，在同一调控序列控制下表达基因重组所得的蛋白质产物。在本发明的一些实施方案中，第一多肽为IL-21或其变体与生物活性多肽(如Fc片段)融合或非融合表达得到的单体蛋白质；第二多肽为IL-21Rα或其变体与生物活性多肽(如Fc片段)融合或非融合表达得到的单体蛋白质。本发明的融合蛋白中，两个或多个基因的编码区之间可由编码肽接头的序列于一个或数个位置融合。肽接头也可用于构建本发明的融合蛋白。
本发明所述的“连接肽(Linker)”在本发明中用于连接IL-21或IL-21Rα与Fc变体，以保证蛋白的正确折叠和稳定性的肽。本发明的“连接肽”优选为(GGGGS)nS，其中n可以为0、1、2、3、4、5或者更多，优选n为2-4。
本发明所述的“IL-21或功能性片段”可以是任何物种的IL-21(白细胞介素21)或其突变体，如人IL-21或非人哺乳动物IL-21或非哺乳动物IL-21。示例性非人哺乳动物如猪、兔、猴、猩猩、鼠等，非哺乳动物如鸡等。优选为人的IL-21或其功能性片段。人野生型白细胞介素21成熟分子的氨基酸序列如SEQ ID NO：9所示，本发明IL-21所有氨基酸位点的编号以SEQ ID NO：9为基准，从N端至C端的顺序编号。
本发明所述的“IL-21功能性片段”指通过一个或多个氨基酸替换、增加或者缺失突变获得的对IL-21生物功能有影响或其他性质发生改变的突变体，通过这类氨基酸变化可以增加或者降低IL-21与其受体之间的相互作用能力；或者通过这类氨基酸变化可以增加或者降低IL-21生物学活性比如其刺激免疫细胞增殖活性；或者通过这类氨基酸变化在IL-21和其受体之间建立共价键或者使共价连接更加稳定等。
本发明所述的“IL-21Rα或其功能性片段”可以是任何物种的IL-21Rα或者其突变体，如人IL-21Rα或非人哺乳动物IL-21Rα或非哺乳动物IL-21Rα。示例性非人哺乳动物如猪、兔、猴、猩猩、鼠等，非哺乳动物如鸡等。优选人的IL-21Rα，更优选的是人的IL-21Rα胞外区部分，简称IL-21Rα(SEQ ID NO：11)。本发明IL-21Rα所有氨基酸位点的编号以SEQ ID NO：11为基准，从N端至C端的顺序编号。
本发明所述的“IL-21Rα功能性片段”，即通过一个或多个氨基酸替换、插入或者缺失突变所得的具有人白细胞介素21受体α活性的分子。
本发明所述的“Fc片段”指的是人免疫球蛋白链恒定区，特别是免疫球蛋白重链恒定区的羧基端或其中的一部分，无抗原结合活性，是抗体分子与效应分子和细胞相互作用的部位。例如，免疫球蛋白Fc区可包括重链CH1、CH2、CH3、CH4的两个或更多结构域与免疫球蛋白铰链区的组合。根据重链恒定区的氨基酸序列，免疫球蛋白可以分为不同的种类，主要有5类免疫球蛋白：IgA、IgD、IgE、IgG和IgM。其中一些还可进一步分成亚类(同种型)，如IgG-1、IgG-2、IgG-3、IgG-4；IgA-1和IgA-2以及不同的基因型。
本发明所述的“Fc片段”优选包括至少一个免疫球蛋白绞链区，以及IgG的CH2和CH3区。更优选包括IgG1的一个CH2结构域，一个CH3结构域和一个免疫球蛋白绞链区，铰链区起始氨基酸位置可以变动。本发明中的Fc的氨基酸序列如SEQ ID NO：13所示。
本发明所述的“药物组合物”表示含有一种或多种本文所述化合物或其生理学上/可药用的盐或前体药物与其它化学组分的混合物，以及其它组分例如生理学/可药用的载体和赋形剂。药物组合物的目的是促进对生物体的给药，利于活性成分的吸收进而发挥生物活性。
本发明中所述的用重组DNA转化宿主细胞的步骤可用本领域技术人员熟知的常规技术进行。获得的转化子可以用常规方法培养，以及表达本发明的基因所编码的多肽。根据所用的宿主细胞，培养过程中所用的培养基可选自各种常规培养基。宿主细胞在适于宿主细胞生长的条件下进行培养。
实施例
以下结合实施例进一步描述本发明，但这些实施例并非限制本发明的范围。
本发明实施例或测试例中未注明具体条件的实验方法，通常按照常规条件，或按照原料或商品制造厂商所建议的条件。参见分子克隆，实验室手册，当代分子生物学方法。未注明具体来源的试剂，为市场购买的常规试剂。
实施例1突变体的选择
选择IL-21和IL-21Rα的晶体复合物结构(PDB ID:3TGX，图1)为初始结构。从结构上统计出位于IL-21和IL-21Rα的接触界面残基，IL-21及IL-21Rα复合物中接触界面残基如下表1所示。
表1 IL-21及IL-21Rα复合物中接触界面残基
除了从以上接触界面筛选外，发明人尝试从更广的范围内筛选能够形成稳定二硫键的组合，通过大量筛选找出了IL-21上的S4、S5、I71和IL-21Rα上的S92、A127，经过多次优选，示例性地优选出9对突变残基，突变组合如下表2所示。
表2IL-21和IL-21Rα复合物的突变组合
实施例2 IL-21及IL-21受体复合物/融合蛋白的构建
本发明提供的IL-21及IL-21Rα复合物由第一多肽和第二多肽组成；其中，第一多肽为人IL-21多肽或其功能性片段；第二多肽为人IL-21Rα多肽或其功能性片段；第一多肽或第二多肽上具有一个或多个氨基酸位点突变成Cys，与对应的第二多肽或第一多肽氨基酸位点上突变成的Cys配对形成二硫键。
本发明通过基因工程方法构建稳定的、有明显抗肿瘤活性的、体内半衰期延长的蛋白复合物，且该复合物分子内包含IL-21或其衍生物和IL-21Rα或其衍生物的Fc融合蛋白分子。
人野生型白细胞介素21成熟分子的氨基酸序列如SEQ ID NO：9所示，本发明IL-21所有氨基酸位点以SEQ ID NO：9氨基端顺序为基准。
人的IL-21Rα胞外区部分，简称IL-21Rα，其氨基酸序列如SEQ ID NO：11所示。本发明IL-21Rα所有氨基酸位点以SEQ ID NO：11氨基端顺序为基准。
示例性的选取一种IL-21/IL-21Rα复合物的使用场景：靶向抗原的重链可变区(VH)通过Linker连接在IL-21Rα上，再通过Hinge(其氨基酸序列如SEQ ID NO：21所示)与抗体的Fc的N端连接；靶向相同抗原的轻链可变区(VL)通过Linker(其氨基酸序列如SEQ ID NO：24所示)连接在IL-21上，制备一种具有靶向性的IL-21/IL-21Rα融合蛋白。示例性的复合物1～9的重链和轻链的氨基酸序列如下表3所示，其中，突变后的Cys用下划线并加粗进行标识。本实施例的Fc的氨基酸序列如SEQ ID NO：13所示。
表3.示例性的复合物的重链和轻链的氨基酸序列
上述融合蛋白可应用于靶向同一抗原或靶点的分子，例如图3B或图3C(所述scfv靶向相同抗原或靶点)的结构，也可用于靶向2个或多个抗原或靶点分子，例如图3A或图3C(所述scfv靶向不同抗原或靶点)，本融合蛋白的应用场景不限于以上举例。
示例性的选取一种IL-21/IL-21Rα复合物的使用场景：以图3A为例制备融合蛋白，一侧为靶向TIGIT的抗体，另一侧为靶向PD-L1的抗体，靶向PD-L1的抗体的重链和轻链氨基酸序列分别如SEQ ID NO：19和SEQ ID NO：20所示。
靶向PD-L1的抗体的轻链氨基酸序列：
靶向PD-L1的抗体的重链氨基酸序列：
实施例3复合物/融合蛋白样品的制备
蛋白瞬转表达
将含有目的基因的质粒通过与转染试剂PEI形成阳离子复合物后，导入到宿主细胞Expi293，质粒在细胞内期间，质粒上的外源基因在细胞内发 生转录翻译，从而得到目的蛋白。
Expi293细胞在37℃、8％二氧化碳、130rpm条件培养，并在转染前通过细胞计数，将2E6的细胞接种至1L摇瓶中，培养体系约为300mL。配制转染复合物准备转染：首先将750μg目标质粒加入到含有15mL Opti-MEM试剂的50mL离心管中，轻轻混匀，标记为A管；将1.5mg转染试剂PEI加入到含有15mL Opti-MEM试剂的50mL离心管中，轻轻混匀后，室温孵育5min，标记为B管；将B管PEI稀释液逐滴加入到A管DNA稀释液中，轻轻混匀后，室温孵育15min，孵育结束后，将PEI-目标质粒复合物加入到Expi293细胞，置于37℃摇床中继续培养。直到D7-D10后收样。
复合物样品的纯化
瞬转细胞表达液经过9000rpm/20min离心，收集上清，再经过0.22μm滤膜除菌过滤。采用ProA亲和层析进行纯化，过程如下：使用AKTA avant150层析设备，用至少5CV平衡缓冲液(10mM PBS)平衡层析柱(如MabSelectSuRe LX，GE)，加载样品至层析柱，使目标蛋白吸附在层析柱上而其他杂质穿透分离。完成上样后使用至少5CV平衡缓冲液(10mM PBS)再次冲洗层析柱，随后使用洗脱缓冲液(20mM NaAc，pH＝3.4)洗脱目标蛋白，收集管中预先加入中和缓冲液(1M Tris，pH＝8.0)，中和缓冲液的加入体积根据洗脱样品的预估含量而定，一般加入10％洗脱体积量。
实施例4经二硫键改造的IL-21/IL-21Rα复合物/融合蛋白凝胶电泳检测
对二硫键改造的IL-21/IL-21Rα复合物进行SDS-PAGE电泳检测，检测结果如图4所示，未进行二硫键改造的复合物(复合物10)在分子量25KD～35KD之间有条带，说明存在游离轻链；复合物1～复合物9在分子量25KD～35KD之间无条带，说明二硫键改造成功。
实施例5靶向部分亲和力检测
TIGIT端结合活性分析
通过FCM实验方法检测双抗分子(TIGIT端)与CHO-TIGIT细胞(表达TIGIT蛋白的CHO细胞)结合活性。配置3％BSA缓冲液：称取4.5g BSA到150mL 1X PBS中，混匀后放置冰上备用；抗体稀释：将受试抗体、阳性对照用3％BSA稀释成初始浓度为800nM，亚型对照稀释成初始浓度为20μg/mL，体积300μL，3倍梯度稀释(100μL+200μL)共10个点；结合活性检测；细胞计数并铺板：将CHO-TIGIT细胞计数后，按100μL,2E+05/孔分到96孔V型板中；先将不同浓度抗体50μL加入到细胞中，2-8℃孵育0.5h；350xg离心5min后，去掉上清，按200μL/孔加入3％BSA；350xg离心5min后，去掉上清，3％BSA配制荧光抗体PE Goat anti-human IgG Fc和 PE Goat anti-mouse IgG Fc(1:500x稀释)，按100μL/孔加入对应的96孔板中，2-8℃孵育30min；350g离心5min，去上清，3％BSA洗一遍细胞；350xg离心5min后，去掉上清，按100μL/孔加入1X PBS，重悬细胞；按照CytoFLEX流式细胞仪标准操作规程上机检测，检测结果见图5，与未进行二硫键改造的分子相比亲和力相当，说明二硫键改造未减弱靶向区的亲和力。
PD-L1端结合活性分析
通过FCM实验方法检测双抗分子(PD-L1端)与CHO-PD-L1细胞结合活性。配置3％BSA缓冲液：称取4.5gBSA到150mL 1XPBS中，混匀后放置冰上备用；抗体稀释：将受试抗体、阳性对照R1123(即复合物10，未经二硫键改造，其重链氨基酸序列如SEQ ID NO：22所示，其轻链氨基酸序列如SEQ ID NO：23所示)用3％BSA稀释成初始浓度为800nM，亚型对照稀释成初始浓度为20μg/mL，体积300μL，3倍梯度稀释(100μL+200μL)共10个点；结合活性检测；细胞计数并铺板：将CHO-PD-L1细胞计数后，按100μL，2E+05/孔分到96孔V型板中；先将不同浓度抗体50μL加入到细胞中，2-8℃孵育0.5h；350xg离心5min后，去掉上清，按200μL/孔3％BSA；350xg离心5min后，去掉上清，3％BSA配制荧光抗体PE Goat anti-human IgG Fc和PE Goat anti-mouse IgG Fc(1:500x稀释)，按100μL/孔加入对应的96孔板中，2-8℃孵育30min；350g离心5min，去上清，3％BSA洗一遍细胞；350xg离心5min后，去掉上清，按100μL/孔加入1XPBS重悬细胞；按照CytoFLEX流式细胞仪标准操作规程上机检测。
阳性对照R1123的重链的氨基酸序列
阳性对照R1123的轻链的氨基酸序列
检测结果见图6，与未进行二硫键改造的分子相比亲和力相当，说明二 硫键改造不会影响靶向区的亲和力。
TIGIT端阻断活性分析
通过FCM实验方法检测双抗分子(TIGIT端)阻断配体与CHO-TIGIT细胞结合活性。配置3％BSA缓冲液：称取4.5gBSA到150mL 1XPBS中，混匀后放置冰上备用；抗体稀释：将受试抗体、阳性对照(R1123，未经二硫键改造)用3％BSA稀释成初始浓度为800nM，亚型对照稀释成初始浓度为20μg/mL，体积300μL，3倍梯度稀释(100μL+200μL)共10个点；结合活性检测；细胞计数并铺板：将CHO-TIGIT细胞计数后，按100μL,2E+05/孔分到96孔V型板中；先将不同浓度抗体50μL加入到细胞中，2-8℃孵育0.5h，再加入50μL配体，2-8℃孵育0.5h；350xg离心5min后，去掉上清，按200μL/孔3％BSA；350xg离心5min后，去掉上清，3％BSA配制荧光抗体PE Goat anti-human IgG Fc和PE Goat anti-mouse IgG Fc(1:500x稀释)，按100μL/孔加入对应的96孔板中，2-8℃孵育30min；350g离心5min，去上清，3％BSA洗一遍细胞；350xg离心5min后，去掉上清，按100μL/孔加入1XPBS重悬细胞；按照CytoFLEX流式细胞仪标准操作规程上机检测，检测结果见图7与未进行二硫键改造的分子相比亲和力相当，说明二硫键改造未减弱靶向区的亲和力。
以上所述实施例的各技术特征可以进行任意的组合，为使描述简洁，未对上述实施例中的各个技术特征所有可能的组合都进行描述，然而，只要这些技术特征的组合不存在矛盾，都应当认为是本说明书记载的范围。
以上所述实施例仅表达了本发明的几种实施方式，其描述较为具体和详细，但并不能因此而理解为对发明专利范围的限制。应当指出的是，对于本领域的普通技术人员来说，在不脱离本发明构思的前提下，还可以做出若干变形和改进，这些都属于本发明的保护范围。因此，本发明专利的保护范围应以所附权利要求为准。

Claims (10)

  1. 一种IL-21及IL-21Rα的多肽复合物，其特征在于，其由第一多肽和第二多肽组成；其中，第一多肽为人IL-21多肽或其功能性片段；第二多肽为人IL-21Rα多肽或其功能性片段；
    优选地，第一多肽或第二多肽上具有一个或多个氨基酸位点突变成Cys，与对应的第二多肽或第一多肽氨基酸位点上突变成的Cys配对形成二硫键；
    其中所述的氨基酸Cys突变位点发生在IL-21多肽或其功能片段上的S4、S5、R10、I13、R14、Q17、I71、R81或K82上和/或所述的氨基酸Cys突变位点发生在IL-21Rα多肽或其功能性片段上的Y36、E38、A71、D72、S92、或A127上。
  2. 根据权利要求1所述多肽复合物，其特征在于，所述氨基酸位点突变选自以下突变组合中的一组或多组：
    1)第一多肽-R81C和第二多肽-E38C；
    2)第一多肽-Q17C和第二多肽-A71C；
    3)第一多肽-R14C和第二多肽-D72C；
    4)第一多肽-S5C和第二多肽-S92C；
    5)第一多肽-S4C和第二多肽-S92C；
    6)第一多肽-R10C和第二多肽-D72C；
    7)第一多肽-I13C和第二多肽-D72C；
    8)第一多肽-I71C和第二多肽-A127C；和/或
    9)第一多肽-K82C和第二多肽-Y36C。
  3. 根据权利要求1～2任一项所述多肽复合物，其特征在于，所述第一多肽的氨基酸序列选自SEQ ID NO：2的第140位-352位氨基酸、SEQ ID NO：4的第140位-352位氨基酸、SEQ ID NO：6的第140位-352位氨基酸、SEQ ID NO：8的第140位-352位氨基酸、SEQ ID NO：10的第140位-352位氨基酸、SEQ ID NO：12的第140位-352位氨基酸、SEQ ID NO：14的第140位-352位氨基酸、SEQ ID NO：16的第140位-352位氨基酸、或SEQ ID NO：18的第140位-352位氨基酸。
  4. 根据权利要求1～3任一项所述多肽复合物，其特征在于，所述第二多肽的氨基酸序列选自SEQ ID NO：1的第129位-266位氨基酸、SEQ ID NO：3的第129位-266位氨基酸、SEQ ID NO：5的第129位-266位氨基酸、SEQ ID NO：7的第129位-266位氨基酸、SEQ ID NO：15的第129位-266位氨基酸、或SEQ ID NO：17的第129位-266位氨基酸。
  5. 根据权利要求1～4任一项所述多肽复合物，其特征在于，所述的第一多肽和/或第二多肽与Fc片段共价连接。
  6. 分离的核酸，其特征在于，所述核酸编码权利要求1～5任一项所述的IL-21及IL-21Rα多肽复合物。
  7. 载体，其特征在于，所述载体含有权利要求6所述的核酸。
  8. 宿主细胞，其特征在于，所述宿主细胞含有权利要求6所述核酸或者权利要求7所述载体。
  9. 药物组合物，其特征在于，所述药物组合物包含权利要求1～5任一项所述的IL-21及IL-21Rα的多肽复合物，和药学上可接受的载体、赋形剂、或稳定剂。
  10. 权利要求1～5任一项所述的IL-21及IL-21Rα多肽复合物、权利要求6所述的核酸、权利要求7所述载体、或权利要求8所述宿主细胞在制备用于治疗疾病的药物中的应用。
PCT/CN2023/072595 2022-01-21 2023-01-17 白细胞介素21及其受体复合物 WO2023138573A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202210077607 2022-01-21
CN202210077607.4 2022-01-21

Publications (1)

Publication Number Publication Date
WO2023138573A1 true WO2023138573A1 (zh) 2023-07-27

Family

ID=87319038

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/072595 WO2023138573A1 (zh) 2022-01-21 2023-01-17 白细胞介素21及其受体复合物

Country Status (3)

Country Link
CN (1) CN116496408A (zh)
TW (1) TW202330583A (zh)
WO (1) WO2023138573A1 (zh)

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006037960A2 (en) * 2004-10-01 2006-04-13 Avidex Ltd. T-cell receptors containing a non-native disulfide interchain bond linked to therapeutic agents
WO2016095642A1 (zh) * 2014-12-19 2016-06-23 江苏恒瑞医药股份有限公司 白细胞介素15蛋白复合物及其用途
CN110448691A (zh) * 2018-05-07 2019-11-15 江苏恒瑞医药股份有限公司 抗pd-1抗体联合il-15蛋白复合物在制备治疗肿瘤的药物中的用途
CN111205361A (zh) * 2018-11-22 2020-05-29 海珂分子（北京）科技有限责任公司 白介素21蛋白（il21）突变体及其应用
CN112534052A (zh) * 2018-07-25 2021-03-19 奥美药业有限公司 全新il-21前药及使用方法
WO2021142471A1 (en) * 2020-01-11 2021-07-15 AskGene Pharma, Inc. Novel masked cytokines and methods of use thereof
CN113135996A (zh) * 2019-12-09 2021-07-20 启愈生物技术(上海)有限公司 一种双特异抗体及其应用
CN113307879A (zh) * 2020-02-27 2021-08-27 启愈生物技术(上海)有限公司 一种taa/ctla-4/il15三功能融合蛋白及其应用
WO2021253360A1 (en) * 2020-06-18 2021-12-23 Proviva Therapeutics (Hong Kong) Limited Activatable procytokines
CN113943374A (zh) * 2021-09-24 2022-01-18 广东菲鹏制药股份有限公司 一种白介素15及其受体的多肽复合物
WO2023046093A1 (zh) * 2021-09-24 2023-03-30 广东菲鹏制药股份有限公司 一种双特异性多肽复合物

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006037960A2 (en) * 2004-10-01 2006-04-13 Avidex Ltd. T-cell receptors containing a non-native disulfide interchain bond linked to therapeutic agents
WO2016095642A1 (zh) * 2014-12-19 2016-06-23 江苏恒瑞医药股份有限公司 白细胞介素15蛋白复合物及其用途
CN110448691A (zh) * 2018-05-07 2019-11-15 江苏恒瑞医药股份有限公司 抗pd-1抗体联合il-15蛋白复合物在制备治疗肿瘤的药物中的用途
CN112534052A (zh) * 2018-07-25 2021-03-19 奥美药业有限公司 全新il-21前药及使用方法
CN111205361A (zh) * 2018-11-22 2020-05-29 海珂分子（北京）科技有限责任公司 白介素21蛋白（il21）突变体及其应用
CN113135996A (zh) * 2019-12-09 2021-07-20 启愈生物技术(上海)有限公司 一种双特异抗体及其应用
WO2021142471A1 (en) * 2020-01-11 2021-07-15 AskGene Pharma, Inc. Novel masked cytokines and methods of use thereof
CN113307879A (zh) * 2020-02-27 2021-08-27 启愈生物技术(上海)有限公司 一种taa/ctla-4/il15三功能融合蛋白及其应用
WO2021253360A1 (en) * 2020-06-18 2021-12-23 Proviva Therapeutics (Hong Kong) Limited Activatable procytokines
CN113943374A (zh) * 2021-09-24 2022-01-18 广东菲鹏制药股份有限公司 一种白介素15及其受体的多肽复合物
WO2023046093A1 (zh) * 2021-09-24 2023-03-30 广东菲鹏制药股份有限公司 一种双特异性多肽复合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HAMMING O J, KANG L, SVENSSON A, KARLSEN J L, RAHBEK-NIELSEN H, PALUDAN S R, HJORTH S A, BONDENSGAARD K, HARTMANN R.: "Crystal structure of interleukin-21 receptor (IL-21R) bound to IL-21 reveals that sugar chain interacting with WSXWS motif is integral part of IL-21R.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 287, no. 12, 16 March 2012 (2012-03-16), US , pages 9454 - 9460, XP002738765, ISSN: 0021-9258, DOI: 10.1074/jbc.M111.311084 *
SHEN SHANLING, SCKISEL GAIL, SAHOO ANUPAMA, LALANI ALMIN, OTTER DOUG DEN, PEARSON JOSH, DEVOSS JASON, CHENG JAY, CASEY STEPHANIE C: "Engineered IL-21 Cytokine Muteins Fused to Anti-PD-1 Antibodies Can Improve CD8+ T Cell Function and Anti-tumor Immunity", FRONTIERS IN IMMUNOLOGY, vol. 11, 8 May 2020 (2020-05-08), pages 1 - 14, XP055854614, DOI: 10.3389/fimmu.2020.00832 *

Also Published As

Publication number Publication date
CN116496408A (zh) 2023-07-28
TW202330583A (zh) 2023-08-01

Similar Documents

Publication Publication Date Title
CA3175728A1 (en) Interleukin-2 mutant and use thereof
TW202214677A (zh) Ｉｌ－２突變體及其應用
CN111138521B (zh) 源自于afp抗原的短肽
JP7207786B2 (ja) インターロイキン２１タンパク質（ｉｌ２１）変異体およびその適用
CN113444182A (zh) 一种靶向递送IgG类抗体的融合蛋白载体及其用途
CN113943374B (zh) 一种白介素15及其受体的多肽复合物
JP2023550191A (ja) Ｄｒ４および／またはｄｒ５を標的とするポリペプチドならびに関連する組成物および方法
CN111499764B (zh) 一种具有促红细胞生成素活性的长效融合蛋白
CN112618698B (zh) 一种人白细胞介素10-Fc融合蛋白的注射制剂
WO2023138573A1 (zh) 白细胞介素21及其受体复合物
CN113667004A (zh) 一种白介素2突变体
WO2022105922A1 (zh) 源自于ssx2抗原的短肽
CN112574315B (zh) 改变效应功能的Fc变体及其融合蛋白
CN118063588A (zh) 一种重组融合蛋白及其应用
CN114316064A (zh) 融合蛋白及其应用
US9896497B2 (en) Toll-like receptor 2 binding epitope and binding member thereto
WO2024131864A1 (zh) 一种il-10单体融合蛋白
WO2023169524A1 (zh) 白细胞介素2突变体以及含有其的复合物
US20230272026A1 (en) A fusion protein comprising an antigen binding domain and a cytokine trimer domain
CN112300261B (zh) 一种衍生自afp的肿瘤抗原短肽
WO2022089418A1 (zh) 重组截短FLT3配体与人抗体Fc的融合蛋白
CN111138522B (zh) 衍生自afp的肿瘤抗原短肽
CN116375880A (zh) 融合蛋白及其制备方法和应用
WO2023030408A1 (zh) TGFβRII突变体及其应用
CN118240058A (zh) Il10突变体、融合蛋白和药物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23742888

Country of ref document: EP

Kind code of ref document: A1